OKUR Stock Forecast & Price Target

OnKure Therapeutics is supported by a strong scientific rationale, as its next-gen PI3Kα program aims to selectively inhibit mutant PI3Kα while sparing wild-type PI3Kα, potentially reducing off-target toxicity and improving the therapeutic index versus prior approaches. Preclinical data for OKI-345 and OKI-355 showed greater cellular selectivity than Eli Lilly’s tersolisib and Relay Therapeutics’ zovegalisib across PI3KαH1047R, PI3KαE545K, and PI3KαE542K models, while IND submissions are anticipated in 1H27. Fundamentally, the company’s $176M cash balance at 2Q, expected to fund operations into 2029, provides a long runway to advance OKI-345 in breast cancer and OKI-355 in vascular anomalies, reinforcing the upside case.

OnKure Therapeutics is facing a more difficult competitive backdrop as Celcuity’s FDA-approved REVTORPYK has already shown strong efficacy in HR+/HER2- disease, with mPFS of 9.3 and 7.4 months versus 2.0 months for fulvestrant alone, raising the bar for any future PI3K-focused entrant. The company’s lead asset, OKI-345, is modeled with only a 15% probability of approval in 1L and 2L HR+, HER2- PI3Ka-mutated metastatic breast cancer, underscoring significant clinical and regulatory uncertainty around its pipeline. With valuation relying on a DCF that already embeds heavy risk and management citing long-term dilution, delays in registrational development, and competitive pressure from other mutant-selective PI3Kα inhibitors, the fundamental outlook remains weak.